ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
124.929,37
-0,59%
S&P 500
5.998,74
0,00%
US Dollar vs BRL
6,0703
1,61%
Bitcoin
95.768,26
-1,53%
Brent Oil
72,745
0,93%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Sigilon Therapeutics Inc (SGTX)

  7. Sigilon Therapeutics Inc (SGTX) Notícias

SGTX

Sigilon Therapeutics (SGTX)

Sigilon Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:SGTX
DataHoraFonteTítuloCódigoCompanhia
21/08/202309:22Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:SGTXSigilon Therapeutics Inc
16/08/202301:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SGTXSigilon Therapeutics Inc
14/08/202308:25PR Newswire (US)Lilly Completes Acquisition of Sigilon TherapeuticsNASDAQ:SGTXSigilon Therapeutics Inc
11/08/202317:28Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:SGTXSigilon Therapeutics Inc
11/08/202317:20Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:SGTXSigilon Therapeutics Inc
11/08/202317:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SGTXSigilon Therapeutics Inc
11/08/202317:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGTXSigilon Therapeutics Inc
10/08/202309:31Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:SGTXSigilon Therapeutics Inc
07/08/202309:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SGTXSigilon Therapeutics Inc
13/07/202309:18Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:SGTXSigilon Therapeutics Inc
29/06/202308:35Dow Jones NewsEli Lilly to Acquire Sigilon TherapeuticsNASDAQ:SGTXSigilon Therapeutics Inc
29/06/202308:04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SGTXSigilon Therapeutics Inc
29/06/202307:57Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:SGTXSigilon Therapeutics Inc
29/06/202307:45PR Newswire (US)Lilly to Acquire Sigilon TherapeuticsNASDAQ:SGTXSigilon Therapeutics Inc
22/05/202317:21Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SGTXSigilon Therapeutics Inc
22/05/202308:30GlobeNewswire Inc.Sigilon Announces Reverse Stock Split of Common StockNASDAQ:SGTXSigilon Therapeutics Inc
09/05/202309:11Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SGTXSigilon Therapeutics Inc
09/05/202308:30GlobeNewswire Inc.Sigilon Therapeutics Reports First Quarter 2023 Financial Results and Business HighlightsNASDAQ:SGTXSigilon Therapeutics Inc
02/05/202310:00PR Newswire (US)Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior AdvisorNASDAQ:SGTXSigilon Therapeutics Inc
18/04/202308:00GlobeNewswire Inc.Sigilon Therapeutics to Present at the Needham Virtual Healthcare ConferenceNASDAQ:SGTXSigilon Therapeutics Inc
06/04/202308:07Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:SGTXSigilon Therapeutics Inc
06/04/202308:03Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:SGTXSigilon Therapeutics Inc
23/03/202318:01Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:SGTXSigilon Therapeutics Inc
14/03/202317:26Edgar (US Regulatory)Annual Report (10-k)NASDAQ:SGTXSigilon Therapeutics Inc
14/03/202317:15GlobeNewswire Inc.Sigilon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business HighlightsNASDAQ:SGTXSigilon Therapeutics Inc
01/03/202318:37Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:SGTXSigilon Therapeutics Inc
10/11/202209:30GlobeNewswire Inc.Sigilon Therapeutics Reports Third Quarter 2022 Financial Results and Business HighlightsNASDAQ:SGTXSigilon Therapeutics Inc
04/08/202217:30GlobeNewswire Inc.Sigilon Therapeutics Reports Second Quarter 2022 Financial Results and Business HighlightsNASDAQ:SGTXSigilon Therapeutics Inc
08/07/202217:58Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:SGTXSigilon Therapeutics Inc
12/05/202217:05GlobeNewswire Inc.Sigilon Therapeutics Reports First Quarter 2022 Financial Results And Business HighlightsNASDAQ:SGTXSigilon Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:SGTX

Seu Histórico Recente

BOV
ATOM3
ATOMPAR ON
BOV
IBOV
Índice Bovespa
BOV
AZEV4
AZEVEDO PN
BOV
BHIA3
Grupo Casas Bahia ON
BOV
HAGA3
HAGA ON
BOV
TELB4
TELEBRAS PN
BOV
AGXY3
Agrogalaxy Participacoes ON
BOV
RNEW4
RENOVA PN
BOV
PMAM3
PARANAPANEMA ON
BOV
LUPA3
LUPATECH ON
BOV
IDIV
Dividend
BOV
BRFS3
BRF S/A ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Economize até 50%* para TRADER BRASIL

1 ano 30%, 2 anos 40% e *3 anos 50%

*Ao longo de 3 anos $ 881.64 apenas $ 440.82